Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy

Eur J Gastroenterol Hepatol. 2006 May;18(5):565-6. doi: 10.1097/00042737-200605000-00021.

Abstract

Anti-TNFalpha drugs are currently used in the treatment of patients with Crohn's disease. Studies have reported neurological side effects occurring after anti-TNFalpha treatment, including infliximab-induced complications.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Crohn Disease / drug therapy*
  • Demyelinating Diseases / chemically induced*
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab